Navigation Links
Anti-cancer drug kicks HIV out of hiding
Date:7/22/2014

A pilot study by HIV researchers from Aarhus University and Aarhus University Hospital in Denmark has shown that an anti-cancer drug can activate hidden HIV. The researchers found that the anti-cancer drug romidepsin increased the virus production in HIV-infected cells between 2.1 and 3.9 times above normal and that the viral load in the blood increased to measurable levels in five out of six patients with HIV infection.

A pilot study

The results were presented today as breaking news at the annual international AIDS conference in Melbourne, Australia. The pilot study is part of a larger study investigating the possibilities of combining activation of HIV and a vaccine to strengthen the ability of the immune system to fight HIV.

The group of researchers from Aarhus University and Aarhus University Hospital has previously shown that the drug panobinostat can activate hidden HIV in the cells but for the first time the researchers have been demonstrated that it is possible to activate hidden virus to levels readably detectable in the blood by standard methods.

Activated HIV leaves traces

HIV can hide in a "state of hibernation" in the so-called CD4 cells. These cells are a part of the body's immune system, but the CD4 cells cannot fight the virus themselves; killer T-cells can. However, killer T-cells cannot tell if a CD4 cell contains "hibernating" HIV virus. That is why HIV continues to be a chronic disease. HIV infection can be kept down by medicine but there is still no cure which can eradicate HIV from the body.

The results presented by the researchers at Aarhus University Hospital and Aarhus University are interesting; when the virus is activated and moves towards the bloodstream it leaves a trace on the outside of the infected CD4 cells. In principle this means that the killer T cells can now trace and destroy the HIV-infected CD4 cells.

Immune system is not strong enough

In addition to measuring the increased viral load in six HIV-infected test persons, the researchers have tested the side effects of the medicine. The test persons experienced transient fatigue and nausea, which are known side effects of romidepsin. And so, the pilot study does not cause immediate concern for special side effects in HIV-infected persons.

Moreover, the researchers have investigated if the total HIV reservoir in the body is lowered when the killer T-cells are now able to trace and destroy the HIV-infected CD4 cells. However, the researchers have not been able to demonstrate that.

The immune system's reaction to the exposed HIV-infected cells may not itself be strong enough to clear the cells from the body. But the mechanism to activate and expose the HIV virus may potentially one day be part of a combination of drugs which together can eradicate HIV infection, says senior researcher and medical doctor Ole Schmeltz Sgaard.

Still a long way to go

The next step is a bigger trial where the researchers will combine romidepsin activation of hidden HIV with a vaccine (vacc-4x) to strengthen the ability of killer T-cells to fight hiv virus.

We have now shown that we can activate a hibernating virus with romidepsin and that the activated virus moves into the bloodstream in large amounts. This is a step in the right direction; but there is still a long way to go and many obstacles to overcome before we can start talking about a cure against HIV, says Ole Schmeltz Sgaard.


'/>"/>

Contact: Ole Schmeltz Søgaard
ole.schmeltz.sogaard@clin.au.dk
45-27-21-59-85
Aarhus University
Source:Eurekalert

Related medicine news :

1. Several FDA-approved anti-cancer drugs induce stem cell tumors, perhaps thwarting therapy
2. Study questions anti-cancer mechanisms of drug tested in clinical trials
3. Study: Autophagy predicts which cancer cells live and die when faced with anti-cancer drugs
4. Pure MHC and Catalent Sign RL21 Anti-Cancer Development Deal
5. A study led by CNIO validates a new anti-cancer therapy based on cell division
6. Metformin's Anti-Cancer Properties Clarified in an Obesity Cell Model of Pancreatic Cancer
7. New understanding of why anti-cancer therapy stops working at a specific stage
8. Anti-cancer drug viewed as possible Alzheimers treatment doesnt work in UF study
9. Overcoming resistance to anti-cancer drugs by targeting cell powerhouses
10. Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies
11. Development of the first way to make large amounts of promising anti-cancer substance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... Chuck E. ... Sensory Sensitive Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, ... other special needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s ...
(Date:2/19/2017)... Carolina (PRWEB) , ... February 19, 2017 , ... The ... evening undergraduate nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged ... initial operations of the nursing department in early 2016. After a nation-wide search, she ...
(Date:2/19/2017)... ... February 19, 2017 , ... "At your fingertips" electronic ... MEDfx and the Delaware Health Information Network (DHIN) have partnered to improve connectivity ... state-wide health information exchange, DHIN stores and shares real-time health data for more ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, ... in the industry, according to the recent NEJM Catalyst Insights Report on the ... the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, ...
(Date:2/18/2017)... ... ... Park Cities Pet Sitter President, Joette White, has been featured on Episode ... The episode, which was posted this week, features a 30-minute interview of White by ... Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business of ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... 2017 Systems Magnetic resonance imaging ... of the organs and tissues in the body with ... The technique does not use ionizing radiation either for ... growth of cancer. MRI is used for a variety ... and orthopedics. Hence, MRI helps in the diagnosis and ...
(Date:2/20/2017)... Feb. 20, 2017  Henry Schein, Inc. (Nasdaq: HSIC), ... products and services to office-based dental, animal ... it has entered into an agreement to ... leading U.S. distributor of anesthesia and surgical ... periodontists. SAS offers controlled and non-controlled pharmaceuticals, ...
(Date:2/20/2017)...  National Decision Support Company (NDSC) announces its ... Imaging platform within the full range of MEDITECH ... foundation for MEDITECH sites, through a directly supported ... Support Mechanism through the MEDITECH EHR. ... the integration of NDSC,s mechanism, which enables provider ...
Breaking Medicine Technology: